EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

MMP1, IL-1β, sTNFR-1, and IL-6 are prognostic factors for patients with unresectable or metastatic renal cell carcinoma treated with immune checkpoint inhibitors

Hirotaka Nagasaka, Takeshi Kishida, Taku Kouro, Yuka Igarashi, Shinichi Takebe, Shotaro Yamamoto, Takuya Kondo, Mitsuyuki Koizumi, Hideyuki Terao, Takahisa Suzuki, Noboru Nakaigawa, Hidetomo Himuro und 2 weitere

International Journal of Clinical Oncology · 2024

DOI: 10.1007/s10147-024-02477-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Clinical Oncology, 2024. Verfasst von Hirotaka Nagasaka und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Kanagawa Cancer Center, Yokohama, Kanagawa, 241-8515, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Interleukin-6, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Few studies have reported reliable prognostic factors for immune checkpoint inhibitors (ICIs) in renal cell carcinoma (RCC). Therefore, we investigated prognostic factors in patients treated with ICIs for unresectable or metastatic RCC.

Methods

We included 43 patients who received ICI treatment for RCC between January 2018 and October 2021. Blood samples were drawn before treatment, and 73 soluble factors in the plasma were analyzed using a bead-based multiplex assay. We examined factors associated with progression-free survival (PFS), overall survival (OS), and immune-related adverse events (irAE) using the Chi-squared test, Kaplan–Meier method, and the COX proportional hazards model.

Results

Patients exhibited a median PFS and OS of 212 and 783 days, respectively. Significant differences in both PFS and OS were observed for MMP1 (PFS, p < 0.001; OS, p = 0.003), IL-1β (PFS, p = 0.021; OS, p = 0.008), sTNFR-1 (PFS, p = 0.017; OS, p = 0.005), and IL-6 (PFS, p = 0.004; OS, p < 0.001). Multivariate analysis revealed significant differences in PFS for MMP1 (hazard ratio [HR] 5.305, 95% confidence interval [CI], 1.648–17.082; p = 0.005) and OS for IL-6 (HR 23.876, 95% CI, 3.426–166.386; p = 0.001). Moreover, 26 patients experienced irAE, leading to ICI discontinuation or withdrawal. MMP1 was significantly associated with irAE (p = 0.039).

Conclusion

MMP1 may be associated with severe irAE, and MMP1, IL-1β, sTNFR-1, and IL-6 could serve as prognostic factors in unresectable or metastatic RCC treated with ICIs. MMP1 and IL-6 were independent predictors of PFS and OS, respectively. Thus, inhibiting these soluble factors may be promising for enhancing antitumor responses in patients with RCC treated with ICIs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsInterleukin-6Immune Checkpoint InhibitorsMatrix Metalloproteinase 1Interleukin-1betaHumansMaleFemaleMiddle AgedAgedPrognosisReceptors, Tumor Necrosis Factor, Type IAdultAged, 80 and overBiomarkers, TumorProgression-Free Survival

Stichwörter der Autor:innen

IL-6Immune checkpoint inhibitor (ICI)Immune-related adverse events (irAE)MMP1Prognostic factorRenal cell carcinoma

Substanzen

Interleukin-6Immune Checkpoint InhibitorsMatrix Metalloproteinase 1Interleukin-1betaIL6 protein, humanMMP1 protein, humanReceptors, Tumor Necrosis Factor, Type IIL1B protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Urology, Kanagawa Cancer Center, Yokohama, Kanagawa, 241-8515, Japan.
  • Department of Urology, Kanagawa Cancer Center, Yokohama, Kanagawa, 241-8515, Japan. kishidat@kcch.jp.
  • Division of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa, 241-8515, Japan.
  • Cancer Vaccine and Immunotherapy Center, Kanagawa Cancer Center, Kanagawa, Japan.
  • Division of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa, 241-8515, Japan. tsasada@kcch.jp.
  • Cancer Vaccine and Immunotherapy Center, Kanagawa Cancer Center, Kanagawa, Japan. tsasada@kcch.jp.

Zitieren

APA

Nagasaka, H., Kishida, T., Kouro, T., Igarashi, Y., Takebe, S., Yamamoto, S., Kondo, T., Koizumi, M., Terao, H., Suzuki, T., Nakaigawa, N., Himuro, H., Wei, F., & Sasada, T. (2024). MMP1, IL-1β, sTNFR-1, and IL-6 are prognostic factors for patients with unresectable or metastatic renal cell carcinoma treated with immune checkpoint inhibitors. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-024-02477-4

Vancouver

Nagasaka H, Kishida T, Kouro T, Igarashi Y, Takebe S, Yamamoto S, et al. MMP1, IL-1β, sTNFR-1, and IL-6 are prognostic factors for patients with unresectable or metastatic renal cell carcinoma treated with immune checkpoint inhibitors. International Journal of Clinical Oncology. 2024. doi:10.1007/s10147-024-02477-4

BibTeX
@article{Nagasaka2024,
  author = {Nagasaka, Hirotaka and Kishida, Takeshi and Kouro, Taku and Igarashi, Yuka and Takebe, Shinichi and Yamamoto, Shotaro and Kondo, Takuya and Koizumi, Mitsuyuki and Terao, Hideyuki and Suzuki, Takahisa and Nakaigawa, Noboru and Himuro, Hidetomo and Wei, Feifei and Sasada, Tetsuro},
  title = {MMP1, IL-1β, sTNFR-1, and IL-6 are prognostic factors for patients with unresectable or metastatic renal cell carcinoma treated with immune checkpoint inhibitors},
  journal = {International Journal of Clinical Oncology},
  year = {2024},
  doi = {10.1007/s10147-024-02477-4}
}
Kostenlos starten →